|
|
 |
|
Viewing report
|
|
|
|
Integrating Diagnostics and Therapeutics for Targeted Therapies, Part II: The Importance of Calculating the Return on Investment
Decision Resources, Inc., Dec 2005, Pages: 10
As the promise of diagnostic/therapeutic combinations is increasingly recognized, pharmaceutical companies must determine best practices in terms of comarketing these combinations. This two-part series is designed to showcase fundamental considerations in diagnostic/drug comarketing plans. Part 1 of this series examined the potential benefit that drug companies can gain from entering into well-planned marketing collaborations with diagnostics companies and presented a framework on which to build these collaborations. In Part 2, we focus on the importance of the financial justification for those collaborations. To highlight the importance of this analysis, we discuss the variables that must be considered when quantifying the expected return. We review three hypotheses often encountered when determining the benefit of a diagnostic, applying to them historical cases in which the relationships between diagnosis and treatment can be measured or analyzed and used as benchmarks when estimating the financial return on new ventures.
Business Implications
- With a broad range of targeted therapies requiring the use of a diagnostic coming to market, comarketing of diagnostics and therapies will become routine. Although theranostics and personalized medicine promise to change the pharmaceutical business model, pharmaceutical companies have little experience in commercializing and marketing diagnostics.
- Pharmaceutical companies need to learn that diagnostics, like the more familiar pharmacotherapies, respond to long-range planning,
branded marketing strategies, and direct selling. Diagnostics can also, in a wide range of circumstances, enhance a therapy’s life-cycle and provide a more-predictable return on marketing investment.
- Although the recent growth in targeted therapy has encouraged the tandem delivery of diagnostics and therapeutics to the physician’s
office, joint sales teams are still not widely employed. Until the economics of a shared salesforce is explored in the field, the responsibility for organizing direct detailing of the diagnostic will be borne by the diagnostics partner.
- The pharma industry should not hesitate to take an early, active role in the collaboration to deliver integrated care. A logical approach
integrating pharma’s creative marketing skills could expand the market, help patients, and provide for better economic returns fo both pharma and diagnostics
Customers who bought this item also bought
Integrating Diagnostics and Therapeutics for Targeted Therapies, Part 1: Optimizing the Comarketing Plan
Molecular Diagnostics - Technologies, Markets and Companies
Companion Diagnostics in Personalized Medicine and Cancer Therapy
Pharma/Medical Device/Diagnostics Licensing and Collaborations � Evaluating the Deal Structure
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Molecular Diagnostics Markets
Nanotechnology: Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics
Targeted Diagnostic Imaging Agents
Point of Care Diagnostic Testing World Markets
Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities
Disruption or Advantage? Update on Companion Diagnostics
Advances in Lab-on-Chip and Microfluidics Technologies for Drug Discovery and Clinical Diagnostics
|
|
|
|
